Skip to content
Companies

CYduct Diagnostics

Nipple aspirate test for early breast cancer risk

Raised to date

$2M

of $2M offered across 1 Form D filing

Last filed
Jul 2, 2026

About

CYduct Diagnostics develops medical devices for the risk assessment, detection, and diagnosis of early-stage breast disease from inside the mammary ducts, where the company says most breast cancers originate. Its lead device, HALO, noninvasively collects nipple aspirate fluid for molecular analysis of duct health, and its MammoView fiberoptic platform lets physicians directly visualize and sample intraductal abnormalities. The company is based in Westport, Connecticut and trades over the counter under the symbol CYDX. It was incorporated in 1986 as Solos Endoscopy and adopted the CYduct Diagnostics name in December 2020.

Takes an intraductal approach, assessing breast health from within the milk ducts using fluid-based molecular diagnostics and direct fiberoptic visualization, rather than relying on external imaging alone.

Funding

  • EquityFiled Jul 2, 2026Form D
    $2M/ $2M

Product

HALO

Breast cancer risk assessment device

A noninvasive device that uses proprietary technology to obtain nipple aspirate fluid for molecular diagnostics, letting physicians and patients assess breast cancer risk from the contents of the mammary ducts.

  • Noninvasive collection of nipple aspirate fluid
  • Sample suitable for molecular, genetic, and proteomic testing
  • Personalized breast cancer risk assessment

Built for

Breast health clinicians and the women they screen and monitor for breast cancer risk

People on file